1. Home
  2. BZH vs AUPH Comparison

BZH vs AUPH Comparison

Compare BZH & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beazer Homes USA Inc.

BZH

Beazer Homes USA Inc.

HOLD

Current Price

$20.22

Market Cap

672.0M

ML Signal

HOLD

Logo Aurinia Pharmaceuticals Inc

AUPH

Aurinia Pharmaceuticals Inc

HOLD

Current Price

$15.93

Market Cap

1.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BZH
AUPH
Founded
1985
1993
Country
United States
Canada
Employees
N/A
N/A
Industry
Homebuilding
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
672.0M
1.6B
IPO Year
1994
1999

Fundamental Metrics

Financial Performance
Metric
BZH
AUPH
Price
$20.22
$15.93
Analyst Decision
Strong Buy
Buy
Analyst Count
3
4
Target Price
$32.00
$17.25
AVG Volume (30 Days)
410.9K
1.1M
Earning Date
01-29-2026
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
1.52
0.55
Revenue
$2,371,555,000.00
$265,808,000.00
Revenue This Year
$7.40
$21.76
Revenue Next Year
$12.09
$16.45
P/E Ratio
$13.34
$28.99
Revenue Growth
1.77
20.62
52 Week Low
$17.37
$6.55
52 Week High
$29.30
$16.54

Technical Indicators

Market Signals
Indicator
BZH
AUPH
Relative Strength Index (RSI) 36.50 55.71
Support Level $19.91 $15.64
Resistance Level $22.04 $16.54
Average True Range (ATR) 0.50 0.38
MACD -0.16 -0.08
Stochastic Oscillator 10.91 57.55

Price Performance

Historical Comparison
BZH
AUPH

About BZH Beazer Homes USA Inc.

Beazer Homes USA Inc is an construction company that focuses on residential construction. The company specializes in single-family housing and multi-unit building construction in states and metro markets. Beazer Homes builds homes and communities that target first-time, move-up, and luxury homebuyers with an average selling price of roughly $300,000. From a geographic perspective, home sales in the western and eastern United States have been the sources of revenue for the company. Its segments involve: West segment that includes Arizona, California, Nevada, and Texas; East segment that includes Delaware, Indiana, Maryland, Tennessee, and Virginia; and Southeast segment which includes Florida, Georgia, North Carolina, and South Carolina.

About AUPH Aurinia Pharmaceuticals Inc

Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.

Share on Social Networks: